文献速递细菌感染、耐药与抗菌药物

中国血流感染中大肠埃希菌和肺炎克雷伯菌携带mcr-1的流行率:多中心纵向研究

Prevalence of mcr-1 in Escherichia coli and Klebsiella pneumoniae recovered from bloodstream infections in China: a multicentre longitudinal study.
PubMed 文献 · Lancet Infect Dis · 2017-01-28

该研究从中国28家医院收集血流感染患者的大肠埃希菌和肺炎克雷伯菌临床分离株,用微量肉汤稀释法筛查黏菌素耐药,PCR检测mcr-1基因。共收集2066株分离株,大肠埃希菌中20株(1%)mcr-1阳性,肺炎克雷伯菌中仅1株(<1%)阳性;所有mcr-1阳性菌株对黏菌素耐药(除1株外MIC 4-32 mg/L),均对替加环素敏感,20株(95%)对哌拉西林-他唑巴坦敏感。

要点

  • 中国血流感染中mcr-1阳性分离株罕见且散发,大肠埃希菌是主要宿主。
  • mcr-1阳性菌株对黏菌素耐药,但对替加环素和哌拉西林-他唑巴坦多保持敏感。
  • 1株mcr-1阳性大肠埃希菌同时产NDM-5,提示耐药基因共存。

核心结论

  • 血流感染中mcr-1阳性分离株罕见、散发,且对多种抗菌药物仍敏感。
  • 大肠埃希菌而非肺炎克雷伯菌是mcr-1基因的主要宿主。

研究设计与样本

  • 多中心纵向研究,从中国28家医院血流感染患者收集大肠埃希菌和肺炎克雷伯菌临床分离株。
  • 用微量肉汤稀释法筛查黏菌素耐药,PCR检测mcr-1基因,并对阳性株进行基因分型、药敏试验和临床数据分析。

主要发现

  • 共收集2066株分离株,包括1495株大肠埃希菌和571株肺炎克雷伯菌。
  • 1495株大肠埃希菌中20株(1%)mcr-1阳性,571株肺炎克雷伯菌中仅1株(<1%)阳性。
  • 21株mcr-1阳性分离株均对替加环素敏感,20株(95%)对哌拉西林-他唑巴坦敏感。
  • 1株mcr-1阳性大肠埃希菌同时产NDM-5;21株阳性分离株克隆多样,mcr-1位于33 kb IncX4质粒和61 kb IncI2质粒上;患者30天死亡率为零。

临床怎么用

  • 临床遇到黏菌素耐药的大肠埃希菌或肺炎克雷伯菌血流感染时,应考虑mcr-1基因检测。
  • mcr-1阳性菌株可能仍对替加环素和哌拉西林-他唑巴坦敏感,可作为治疗参考。

局限性

  • 需进一步研究阐明该新型耐药基因的临床影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Polymyxin antibiotics are used as last-resort therapies to treat infections caused by multidrug-resistant Gram-negative bacteria. The plasmid-mediated colistin resistance determinant MCR-1 has been identified in Enterobacteriaceae in China. We did this study to investigate the prevalence of the mcr-1 gene in clinical isolates from patients with bloodstream infections in China. METHODS: Clinical isolates of Escherichia coli and Klebsiella pneumoniae were collected from patients with bloodstream infections at 28 hospitals in China, then screened for colistin resistance by broth microdilution and for the presence of the mcr-1 gene by PCR amplification. We subjected mcr-1-positive isolates to genotyping, susceptibility testing, and clinical data analysis. We established the genetic location of mcr-1 with Southern blot hybridisation, and we analysed plasmids containing mcr-1 with filter mating, electroporation, and DNA sequencing. FINDINGS: 2066 isolates, consisting of 1495 E coli isolates and 571 K pneumoniae isolates were collected. Of the 1495 E coli isolates, 20 (1%) were mcr-1-positive, whereas we detected only one (<1%) mcr-1-positive isolate among the 571 K pneumoniae isolates. All mcr-1-positive E coli and K pneumoniae isolates were resistant to colistin, with minimum inhibitory concentrations values in the range of 4-32 mg/L, except for one E coli isolate that had a minimum inhibitory concentration less than or equal to 0·06 mg/L. All 21 mcr-1-positive isolates were susceptible to tigecycline and 20 isolates (95%) were susceptible to the carbapenem and β-lactamase inhibitor combination piperacillin and tazobactam. One mcr-1-positive E coli isolate also produced NDM-5, which confers resistance to beta-lactam antibiotics. The 21 mcr-1-positive isolates were clonally diverse and carried mcr-1 on two types of plasmids, a 33 kb IncX4 plasmid and a 61 kb Inc12 plasmid. The 30 day mortality of the patients with bloodstream infections caused by mcr-1-positive isolates was zero. INTERPRETATION: mcr-1-positive isolates from bloodstream infections were rare, sporadic, and remained susceptible to many antimicrobial agents. E coli, rather than K pneumoniae, was the main host of the mcr-1 gene. Further studies are needed to clarify the clinical impact of this novel resistance gene. FUNDING: National Natural Science Foundation of China.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Quan J, Li X, Chen Y, et al. Prevalence of mcr-1 in Escherichia coli and Klebsiella pneumoniae recovered from bloodstream infections in China: a multicentre longitudinal study. Lancet Infect Dis. 2017. PMID: 28139430. doi:10.1016/S1473-3099(16)30528-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。